# Trastuzumab Deruxtecan
人気のポッドキャストエピソード
更新しました:
trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). It is licensed for the treatment of breast cancer, non-small cell lung cancer (NSCLC), gastric or gastroesophageal adenocarcinoma. Trastuzumab binds to and blocks signaling through epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth.
7 28 2025
Hi, This Week in Medicine, we will be discussing
First we will be discussing articles in New England Journal of Medicine
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
Tarlatam…
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Host: Jacob Sands, MD
Guest: Julia Rotow, MD
In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why th…
Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, VIKTORIA1, evERA, DESTINY, ASCENT, TROPION
In this episode of the Oncology Brothers podcast, we are joined by Dr. Virginia Kaklamani from UT San Antonio to discuss the practice changing/informing findings from ESMO 2025, particularly in the realm of breast cancer.
We dived deep into the most impactful studies, including:
MonarchE/NATALE…
S2 Episode 3: Recent Changes in the Management of Metastatic HER2-Positive Breast Cancer
Drs Kathy Miller and Sara Tolaney discuss changes in the management of first-line metastatic HER2-positive disease and the DESTINY-Breast09 trial results.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002984. The topics and discussi…
S3 Ep56: A Look Back at 2022 FDA Approvals in Oncology
In this special episode of “The Vitals,” we ring in the New Year by combing through 2022 FDA approvals. Listen as associate editor, Lindsay Fischer, recounts key approvals on a month-by-month basis, with input from some of the investigators from behind the research. To read the full information sur…
Antibody-Drug Conjugates and Endometrial Cancer: Combinations, Response Rates, and Clinical Trials
Drs Ursula A. Matulonis and Kathleen N. Moore discuss the different aspects of antibody-drug conjugates (ADCs) in endometrial cancer, medications that are currently available, and promising HER2 ADCs.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.co…
JTO Insights: May 2026
In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the May issue of the Journal of Thoracic Oncology. Dr. Bonnie Ky, Founder’s Professor of Cardio-Oncology at the Perelman School of Medicine, University of Penn…
HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:
Introduction (0:00)
Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52)
Available Data with and Practical Appli…
HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O’Malley and Dr Brian M Slomovitz, moderated by Dr O’Malley, including the following topics:
Introduction (0:00)
Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52)
Available Data with and Practical Applicati…
HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O’Malley and Dr Brian M Slomovitz, moderated by Dr O’Malley, including the following topics:
Introduction (0:00)
Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52)
Available Data with and Practical Applicati…
ポッドキャスト検索エンジン
当社の Web サイトを使用して、人、場所、トピックごとに 3,826,057 ポッドキャストや 195,988,214 エピソードを検索できます。
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
